EXTRANODAL NK/T-CELL LYMPHOMA
Clinical trials for EXTRANODAL NK/T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new EXTRANODAL NK/T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for EXTRANODAL NK/T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered donor cells take aim at tough blood cancers in early trial
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for rare blood cancer: experimental drug IMC-001 tested in 23 patients
Disease control OngoingThis study tests an experimental drug called IMC-001 in 23 adults with a rare lymphoma (NK/T-cell) that has returned or stopped responding to prior therapy. The goal is to see if the drug can shrink tumors and to check for side effects. Participants receive IMC-001 and are monito…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: ImmuneOncia Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC